Literature DB >> 21925116

Monocytes to functional dendritic cells is often a bridge too far for cancer therapy.

William F Carson, Steven L Kunkel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21925116      PMCID： PMC3482134          DOI： 10.1016/j.trsl.2011.04.002

Source DB:  PubMed          Journal:  Transl Res        ISSN： 1878-1810            Impact factor:   7.012


× No keyword cloud information.
  14 in total

1.  Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial.

Authors:  Susan E Krown; Jeannette Y Lee; Lan Lin; Margaret A Fischl; Richard Ambinder; Jamie H Von Roenn
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

2.  Type I IFNs enhance the terminal differentiation of dendritic cells.

Authors:  T Luft; K C Pang; E Thomas; P Hertzog; D N Hart; J Trapani; J Cebon
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

3.  Defective dendritic cell generation from monocytes is a potential reason for poor therapeutic efficacy of interferon α2b (IFNα2b) in cervical cancer.

Authors:  Soumyabrata Roy; Shyamal Goswami; Anamika Bose; Kuntal Kanti Goswami; Koustav Sarkar; Krishnendu Chakraborty; Tathagata Chakraborty; Smarajit Pal; Atanu Haldar; Parthasarathi Basu; Jaydip Biswas; Rathindranath Baral
Journal:  Transl Res       Date:  2011-04-09       Impact factor: 7.012

4.  Lack of efficacy of interferon-alpha therapy in recurrent, advanced cervical cancer.

Authors:  S Wadler; R D Burk; D Neuberg; R Rameau; C D Runowicz; G Goldberg; F McGill; R Tachezy; R Comis; J Edmonson
Journal:  J Interferon Cytokine Res       Date:  1995-12       Impact factor: 2.607

Review 5.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Authors:  Pawel Kalinski; Hideho Okada
Journal:  Semin Immunol       Date:  2010-04-20       Impact factor: 11.130

Review 6.  The interferon antiviral response: from viral invasion to evasion.

Authors:  Nathalie Grandvaux; Benjamin R tenOever; Marc J Servant; John Hiscott
Journal:  Curr Opin Infect Dis       Date:  2002-06       Impact factor: 4.915

7.  The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth.

Authors:  Karen A Cavassani; William F Carson; Ana Paula Moreira; Haitao Wen; Matthew A Schaller; Makoto Ishii; Dennis M Lindell; Yali Dou; Nicholas W Lukacs; Venkateshwar G Keshamouni; Cory M Hogaboam; Steven L Kunkel
Journal:  Blood       Date:  2010-02-03       Impact factor: 22.113

8.  Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.

Authors:  Yung-Chi Chang; Tse-Ching Chen; Chun-Ting Lee; Chih-Ya Yang; Hsei-Wei Wang; Chao-Ching Wang; Shie-Liang Hsieh
Journal:  Blood       Date:  2008-03-18       Impact factor: 22.113

9.  Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.

Authors:  H M Kantarjian; T L Smith; S O'Brien; M Beran; S Pierce; M Talpaz
Journal:  Ann Intern Med       Date:  1995-02-15       Impact factor: 25.391

10.  Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response.

Authors:  Haitao Wen; Yali Dou; Cory M Hogaboam; Steven L Kunkel
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.